Biophan Begins Integration of AMRIS Operations; Letter of Intent Extended.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, announced today that it has begun the integration of AMRIS operations into Biophan and expects to close all related paperwork within the next few weeks. An extension of the Letter of Understanding was signed on Monday, in Castrop-Rauxel, Germany.

"We have spent the past week in Germany, meeting with AMRIS and MRC, a subsidiary AMRIS is acquiring, which conducts consulting and testing, and with Michael Friebe, Ph.D., AMRIS founder and President, Andreas Melzer, M.D., AMRIS' Scientific Director and Chief Technology Officer, Gregor Schaefers, Managing Director of MRC, and with their customers and ours, planning the integration of Biophan-Europe. Things are going well and we will close the paperwork for the three company integration within the next few weeks. We extended the letter of understanding to allow us to comply with all related U.S. and German laws," stated Michael Weiner, CEO of Biophan and Michael Friebe, CEO of AMRIS, in a joint statement made in Castrop-Rauxel at the headquarters of AMRIS, which is being renamed Biophan-Europe.

"While in Germany we met with many customers and prospects of Biophan and AMRIS to explore integration issues, including meetings with Boston Scientific personnel to explore how AMRIS will assist Biophan in the support of Boston Scientific. Boston Scientific has a joint development agreement with Biophan across several Boston Scientific divisions, and also has an existing relationship with AMRIS and MRC," stated Michael Weiner.

AMRIS technologies and facilities allow for a significant expansion of Biophan's capabilities, including access to dozens of MRI devices and components through the AMRIS facilities and those of its affiliate, Tomovation, also headed by Dr. Friebe. Tomovation companies distribute, install, and refurbish MRI devices for all the major MRI companies, and this significantly expands the availability of devices for testing, including access to its unique animal testing facilities which can do MRI imaging of very large animals including horses, sheep and large farm swine. Under the terms of the expanding relationship, these facilities will also be made available to Biophan-Europe. Tomovation has ongoing working relationships with Siemens, Philips, and G.E.

"Successful development of MRI-safe and image-compatible medical devices requires extensive testing across a variety of MRI devices, with varying coil types, magnet sizes, and RF capabilities during both the early stage design phase and the later stage clinical trial phases. As the expansion of MRI-safe and image-compatible medical devices continues and expands, both Biophan and its customers, as well as companies pursuing development of their own MRI-safe and image-compatible devices, need access to equipment and expertise covering the full range of MRI devices installed in the field all around the world. AMRIS is quite unique in this regard, and significantly expands and complements the capabilities already provided by Biophan's relationships," Weiner explained.

About AMRIS GmbH

AMRIS is a developer of active MRI systems for enhanced visualization and therapy in the MRI environment. Among the company technologies are advanced MRI-compatible and active endovascular stents, filters, valves, occluders, and catheters. AMRIS is also the holder of two issued U.S. patents and multiple pending U.S. and European patents. The company is based in Castrop-Rauxel and Gelsenkirchen, Germany. More information can be found at www.amris.de

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin-film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 104 U.S. patents, licenses, or applications. This total includes 28 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.